SCHEMBL16593261

SCHEMBL16593261

Cc1ccnc2ccn(S(=O)(=O)c3ccccc3)c12

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.58
CYP2C19 P33261 1/20 0.48
RAPGEF4 Q8WZA2 1/20 0.46
HTR6 P50406 8/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
BRD4 O60885 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.40
ALDH3A1 P30838 1/20 0.40
NOD1 Q9Y239 1/20 0.40
PIK3C3 Q8NEB9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30743569 0.88 L3MBTL1 (0.51) METRAPGEF4HTTALDH1A1TSHR
SCHEMBL16593216 0.82 MET (0.58) METCYP2C19HTR6HTTMEN1
SCHEMBL16593220 0.81 MET (0.57) METCYP2C19HTR6HTTMEN1
SCHEMBL1672537 0.77 CYP2C19 (0.58) METCYP2C19RAPGEF4HTR6HTT
SCHEMBL21295073 0.75 MET (0.65) METCYP2C19HTR6HTTMEN1
SCHEMBL29847193 0.75 MET (0.65) METCYP2C19HTR6HTTMEN1
SCHEMBL30743470 0.74 L3MBTL1 (0.49) METRAPGEF4HTTMEN1ALDH1A1
SCHEMBL3705420 0.74 MET (1.00) METCYP2C19RAPGEF4HTR6HTT
SCHEMBL14727085 0.74 HTR6 (0.58) CYP2C19RAPGEF4HTR6HTTMEN1
SCHEMBL29847431 0.74 MET (1.00) METCYP2C19RAPGEF4HTR6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489237-B1 4-AZAINDOLE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2020-05-13 EP disclosed
EP-3489237-A1 4-AZAINDOLE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2019-05-29 EP disclosed
EP-3052496-B1 4-AZAINDOLE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2018-11-28 EP disclosed
US-10072005-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-09-11 US disclosed
US-20180208593-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-07-26 US disclosed
US-20180208593-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-07-26 US disclosed
US-20180208593-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-07-26 US disclosed
US-9926312-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-03-27 US disclosed
US-9926312-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-03-27 US disclosed
US-9926312-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-03-27 US disclosed
US-20160244445-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-25 US disclosed
US-20160244445-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-25 US disclosed
US-20160244445-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-25 US disclosed
EP-3052496-A1 4-AZAINDOLE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2016-08-10 EP disclosed
WO-2015049574-A1 4-AZAINDOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-09 WO disclosed
WO-2015049574-A1 4-AZAINDOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-09 WO disclosed
US-20150094328-A1 4-Azaindole Derivatives EISAI R&D MAN CO LTD (JP) 2015-04-02 US disclosed
US-20150094328-A1 4-Azaindole Derivatives EISAI R&D MAN CO LTD (JP) 2015-04-02 US disclosed
US-20150094328-A1 4-Azaindole Derivatives EISAI R&D MAN CO LTD (JP) 2015-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072005-B2 4-azaindole derivatives CHRM1, CHRM4, CHRM2 MET 4243/4885CYP2C19 1954/4885RAPGEF4 465/4885
US-20160244445-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 MET 4243/4885CYP2C19 1954/4885RAPGEF4 465/4885
US-20180208593-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 MET 4243/4885CYP2C19 1954/4885RAPGEF4 465/4885
US-20150094328-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 MET 4243/4885CYP2C19 1954/4885RAPGEF4 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.